Abstract
Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright
| Original language | English (US) |
|---|---|
| Pages (from-to) | 751-757 |
| Number of pages | 7 |
| Journal | European Respiratory Journal |
| Volume | 36 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 1 2010 |
Fingerprint
Keywords
- Chronic obstructive pulmonary disease
- Inhaled corticosteroids
- Mortality
- Pneumonia
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. / Malo De Molina, R.; Mortensen, E. M.; Restrepo, Marcos; Copeland, L. A.; Pugh, M. J V; Anzueto, Antonio R.
In: European Respiratory Journal, Vol. 36, No. 4, 01.10.2010, p. 751-757.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
AU - Malo De Molina, R.
AU - Mortensen, E. M.
AU - Restrepo, Marcos
AU - Copeland, L. A.
AU - Pugh, M. J V
AU - Anzueto, Antonio R
PY - 2010/10/1
Y1 - 2010/10/1
N2 - Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright
AB - Recent studies suggest that use of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) may be associated with a higher incidence of pneumonia. However, it is unclear whether COPD subjects on ICS who develop pneumonia have worse outcomes. Therefore, our aim was to examine the association of prior outpatient ICS therapy with mortality in hospitalised COPD subjects with pneumonia. We included subjects ≥64 yrs of age, hospitalised with pneumonia in US Veterans Affairs hospitals, and assessed the association of ICS exposure with mortality for hospitalised COPD subjects with pneumonia in a covariate-adjusted regression model. We identified 6,353 subjects with a diagnosis of pneumonia and prior COPD, of whom 38% were on ICS. Mortality was 9% at 30 days and 16% at 90 days. In regression analyses, outpatient ICS therapy was associated with lower mortality at both 30 days (OR 0.76, 95% CI 0.70-0.83), and 90 days (OR 0.80, 95% CI 0.75-0.86). Outpatient therapy with ICS was associated with a significantly lower 30- and 90-day mortality in hospitalised COPD patients with pneumonia. Copyright
KW - Chronic obstructive pulmonary disease
KW - Inhaled corticosteroids
KW - Mortality
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=77957855131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957855131&partnerID=8YFLogxK
U2 - 10.1183/09031936.00077509
DO - 10.1183/09031936.00077509
M3 - Article
C2 - 20413535
AN - SCOPUS:77957855131
VL - 36
SP - 751
EP - 757
JO - Acta tuberculosea Scandinavica
JF - Acta tuberculosea Scandinavica
SN - 0903-1936
IS - 4
ER -